Mindray Medical International Limited
Mindray believes that the new M7 system provides good value to the customer by combining an economical price with differentiating attributes. This higher-end segment of the ultrasound business has recently experienced tremendous growth as more and more healthcare providers acquire sophisticated capability but in compact and portable form. Mindray hopes to capitalize on this shift in hospital purchasing behavior with its M7 offering, which will combine value and quality features, not always found in portable machines.
In addition to releasing the M7 system in the U.S. , Mindray is engaged in other technology upgrades as well, such as the M5 system. The company remains committed to providing clinicians with the latest technology that enhances patient care. Mindray believes that its progress, with the M7 and M5 systems, demonstrates its keenness to impart diagnostic confidence to clinicians using the company's products.
With its operational headquarters in Shenzhen , China, Mindray is a global Chinese medical device company, which focuses on three segments: the manufacture and sale of patient monitoring devices, diagnostic imaging systems and instruments for In-Vitro diagnostics.
MINDRAY MEDICAL (MR
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.